Skip to main content
More Search Options
A member of our team will call you back within one business day.
Lawrence J. Solin, MD, FACR, FASTRO, Chairman of the Department of Radiation Oncology at Einstein Healthcare Network, is the lead researcher in a ground-breaking clinical trial that uses a new test to determine the best course of treatment for a common form of early-stage breast cancer. The results of the study have been published in the Journal of the National Cancer Institute.
Dr. Solin in the news:
The Oncotype DX® test can predict the risk of recurrence of breast cancer in patients withDCIS (ductal carcinoma in-situ), the most common type of early or pre-invasive breast cancer, also called "Stage 0".
The Oncotype DX® test used in Dr. Solin’s clinical trial can spare patients with a lower risk of recurrence rounds of radiation as part of their treatment plan. The test was developed by Genomic Health, Inc..
The clinical trial was a collaboration with ECOG, the Eastern Cooperative Oncology Group, a cooperative of doctors, researchers and healthcare professionals formed in 1955 to conduct clinical trials. Results were released at the San Antonio Breast Cancer Symposium in December, 2011.
or Browse Names A-Z